George A. Fisher Jr.

Clinical Focus

• Cancer > GI Oncology
• Colorectal Cancer
• Colorectal Cancer - Medical Oncology
• Gastrointestinal Cancers
• Gastrointestinal Cancers - Medical Oncology

Administrative Appointments

• Director, Cancer Clinical Trials Office (2004 - present)

Professional Education

• Fellowship: Stanford University Medical Center, CA (1993)
• Residency: Stanford University Medical Center, CA (1989)
• Internship: Stanford University Medical Center, CA (1988)
• Medical Education: Stanford University School of Medicine, CA (1987)
• BS, Stanford University, Biology (1976)

Research Interests

The research program focuses on clinical trials involving new investigational agents for the treatment of a wide range of cancers. Active clinical trials include studies involving doxorubicin and taxol and agents that reverse resistance to these drugs, such as PSC 833.

Other interests include phase I and II studies using anti-sense DNA, targeting PKC-alpha in ovarian cancer and the role of gene-modified autologous T cells engineered to recognize the TAG-72 antigen on colon cancer cells.

Publications

• Phase II study of imatinib in unresectable hepatocellular carcinoma. Lin AY, Fisher GA, So S, Tang C, Levitt L "Am J Clin Oncol" 2008 ; 1 (31) : 84-8
• Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Schellenberg D, Goodman KA, Lee F, Chang S, Kuo T, Ford JM, Fisher GA, Quon A, Desser TS, Norton J, Greco R, Yang GP, Koong AC "Int J Radiat Oncol Biol Phys" 2008 ; 3 (72) : 678-86
• Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Telli ML, Witteles RM, Fisher GA, Srinivas S "Ann Oncol" 2008 ; 9 (19) : 1613-8
• A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer. Fisher GA, Kuo T, Ramsey M, Schwartz E, Rouse RV, Cho CD, Halsey J, Sikic BI "Clin Cancer Res" 2008 ; 21 (14) : 7074-9
• Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer. Cabebe E, Fisher GA "Expert Opin Investig Drugs" 2007 ; 4 (16) : 467-76